Healthcare Watch List: Oncothyreon (NASDAQ:ONTY), Corcept Therapeutics Incorporated (NASDAQ:CORT), Aastrom Biosciences (NASDAQ:ASTM), Durata Therapeutics (NASDAQ:DRTX)

Corcept Therapeutics (NASDAQ:CORT) Director Longitude Venture Partners L.P sold 250,000 shares of the company’s stock on the open market in a transaction dated Friday, May 2nd. The stock was sold at an average price of $4.11, for a total value of $1,027,500.00. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 5.06% percent to $ 4.15 yesterday on volume of 319,314 shares. The intra-day range of the stock was $ 3.80 – 4.15. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $ 417.40 million.

Aastrom Biosciences Inc (NASDAQ:ASTM) entered into a definitive agreement to acquire Sanofi’s (NYSE:SNY) Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks. Aastrom Biosciences Inc (NASDAQ:ASTM)’s stock on May 5, 2014 reported an increase of 7.38% to the closing price of $ 4.51. Its fifty two weeks range is $ 3.14 – 86.00. The total market capitalization recorded $ 27.77 million. The overall volume in the last trading session was 531,982 shares. In its share capital, Aastrom Biosciences Inc (NASDAQ:ASTM) has 6.19 million outstanding shares.

Durata Therapeutics (NASDAQ:DRTX) has been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the company, American Banking & Market News reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. On Friday, shares of Durata Therapeutics Inc (NASDAQ:DRTX) advanced 5.78% to close the day at $ 14.27. Company monthly performance is recorded as 4.08%. Durata Therapeutics Inc (NASDAQ:DRTX)quarterly revenue growth is 38.68%.

Oncothyreon (NASDAQ:ONTY)’s share price fell 7.8% during mid-day trading on Friday following a weaker than expected earnings announcement, AnalystRatings Network reports. Oncothyreon Inc (USA) (NASDAQ:ONTY) stock performance was 6.34% in last session and finished the day at $ 2.85. Traded volume was 301,661 shares in the last session and the average volume of the stock remained 852,469 shares. The beta of the stock remained 1.07. Oncothyreon Inc (USA) (NASDAQ:ONTY) insider ownership is 0.40%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone